PANDA Gym: Automated Assessment of Neurodevelopment in Infants at Risk for Motor Disability
Launched by UNIVERSITY OF PENNSYLVANIA · Mar 23, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The PANDA Gym clinical trial is studying how to detect early signs of motor delays or impairments in infants who may be at risk for development issues. By using advanced sensors and computer technology, the researchers aim to create simple and accurate tools that can help identify these delays early on. This is important because catching these issues early can lead to better treatment options and improved health outcomes for children.
To participate in this study, infants between 0 to 6 months old are eligible. This includes infants who have had early brain injuries, such as those caused by strokes or other medical conditions, as well as healthy infants with no history of brain injury. Additionally, infants who were born prematurely and have certain medical challenges may also qualify. Participants will undergo assessments that will help researchers learn more about their development. This study is currently recruiting, so if you think your child might be eligible, you can reach out for more information.
Gender
ALL
Eligibility criteria
- • Infants, male and female, between 0-6 months (Infants older than 6 months before initial enrollment will be excluded).
- * Infants with early brain injury (EBI):
- • Hydrocephalus
- • Hypoxic-ischemic encephalopathy (HIE)
- • Periventricular leukomalacia (PVL)
- • Intraventricular hemorrhage (IVH)
- • Stroke
- * Healthy infants (controls):
- • o No history of early brain injury (EBI)
- * Infants without EBI/risk for future disability:
- • Infants without known brain injuries, but with a history of preterm birth less than 32-week gestation with significant medical problems, difficulty eating, or who lack head control at 4 months of age or later will be classified as moderate risk.
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Michelle J Johnson, PhD
Principal Investigator
The University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials